21.14
+1.54%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Dayang Biotech Group Co
Its shares trade on Shenzhen under the ticker 003017.SZ. It has been listed since 26 October 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.05bn and net income of CN¥99.9m. At that date it held total assets of CN¥1.82bn and shareholders' equity of CN¥1.13bn.
Zhejiang Dayang Biotech Group Co., Ltd. engages in the production and sales of potassium salt and veterinary drugs. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2020-10-26. The firm's main products include potassium carbonate, potassium bicarbonate, amproline hydrochloride, 2-chloro-6-fluorobenzaldehyde, etc. Its products are used in food, pesticide, fertilizer, medicine and glass fields. The firm conducts its businesses within the Chinese market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 26 Oct 2020
- Employees
- 897
- Website
- dyhg.com ↗
Leadership
Pay as last reported
- Mr. Yanggui ChenChairman, Executive Director, since 2009CN¥633,600
- Mr. Xianyu WangVice Chairman of the Board, Executive Deputy General Manager, since 2009CN¥535,100
- Ms. Xujun ChenChief Financial Officer, General Manager, Director, since 2009CN¥404,200
- Mr. Weijun GuanDeputy General Manager, Director, since 2009CN¥480,200
- Mr. Yongsheng QiuDeputy General Manager, Director, since 2009CN¥501,800
- Mr. Jiangfeng BaoDeputy General Manager
- Mr. Jianfei YeDeputy General ManagerCN¥637,300
- Mr. Xuping XuSecretary of the BoardCN¥402,300
- Mr. Guoping WangDirector
- Ms. Qiuyan HanIndependent DirectorCN¥71,700
- Mr. Yan JiangIndependent DirectorCN¥71,700
- Mr. Aimin ZengIndependent DirectorCN¥71,700
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Dayang Biotech Group produces potassium carbonate for food and fertilizer applications.
- The company's veterinary drugs like amproline hydrochloride support animal health sectors.
- 897 employees ensure stable production and sales operations in China and overseas.
Weaknesses
- Limited product range beyond potassium salts and veterinary drugs in the Chemicals sector.
- Dependence on Chinese market for primary revenue generation and business expansion.
- No mention of international market diversification strategies in the provided facts.
Opportunities
- Expanding potassium salt applications in the growing food and pesticide industries.
- Increasing demand for veterinary drugs in the global animal health market.
- Potential growth in overseas markets for chemical products like 2-chloro-6-fluorobenzaldehyde.
Threats
- Competition from other Chinese Chemicals firms in the domestic market.
- Regulatory changes affecting chemical production and sales in China.
- Economic fluctuations impacting the global demand for potassium salts and veterinary drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.